The 2020 Digital Learning Journey on Growth Disorders

The 2020/1 Blended Learning Journey on Metastatic Renal Cell Carcinoma (mRCC)

 

LIVE WEBINAR for EMEA: Saturday, 20 March 2021 from 14:00 to 15:00 CET

LIVE WEBINAR for APAC: Saturday, 24 April 2021 from 11:00 to 12:00 CEST

OVERVIEW

Renal Cell Carcinoma (RCC) is a common tumor of the elderly, which has consistently increased in incidence over the past decade. While operative techniques have advanced in recent years and now offer renal preservation and minimal operative trauma where possible, adjuvant measures are not established. Medical treatment remains mostly confined to those with relapsed or metastatic disease, when local therapies are not suitable. The first wave of medical treatments for RCC consisted of cytokines, which had some impact on patient prognosis (overall survival increased to a median of 13 months), but clearly lacked efficacy. Unraveling the molecular carcinogenesis of clear cell RCC spurred the development of targeted therapies, tyrosine kinase inhibitors (TKI), which inhibit the tumor vasculature and have noticeably improved the efficacy of RCC medical treatment. More recently, check point inhibitors (CPI) have entered the therapeutic arena – the latest milestone of clinical development. These tools allow further optimization of treatment by permitting combinations of different therapies. Today, first-line therapies are composed of CPI-based combinations, which have shifted median overall survival expectation to >40 months.

These live webinars bring together a panel of international experts, who will discuss the rapid development of medical treatments with a particular focus on contemporary medical treatment in advanced or metastatic RCC.

TARGET AUDIENCE

These webinars are designed for Oncologists, Urologists and specialists involved in the diagnosis and management of patients with metastatic renal cell carcinoma (mRCC).

CME ACCREDITATION

The 2020/1 Blended Learning Journey on Metastatic Renal Cell Carcinoma (mRCC) will be submitted for accreditation to the European Accreditation Council for Continuing Medical Education (EACCME®).

LANGUAGE

The official language of these live educational programs is English.

For information about the program, please contact:

Scientific Seminars International Foundation
CME Manager: Flaminia Masprone
T +39 380 1504116 – F +39 06 4827169
info@scientificseminars.com

This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.